Autism Spectrum Disorder Referrals to a Rural Hospital in the Past Two Years – A Retrospective Evaluation

Main Article Content

Mert Besenek

Abstract

Objective:   In addition to the core symptoms of Autism Spectrum Disorder (ASD); symptoms such as aggression, self-harm, impulsivity, hyperactivity, anxiety, and mood problems are also often present. Medication use is frequent and studies report that 27-40% of ASD patients use at least one psychotropic medication. We aimed to examine the clinical and sociodemographic features and treatment modalities of ASD patients who were referred to a rural hospital in the last two years.


Material and Methods: Age, gender, mean diagnosis age (MDA), type of ASD, psychiatric symptoms, medication (if they use one) types, and doses were recorded for 200 children with ASD (who were referred between August 2018 – August 2020) were retrospectively evaluated. Also, patients who were diagnosed with “childhood autism (CA)” and “other ASD diagnoses” were compared.


Results: The majority of the patients were male, the MDA value of the all patients was 4.56 (±2.2) years and there were no significant differences between groups regarding MDA (p = 0.053). Most frequently seen psychiatric symptoms were behavioral (33%) and attention problems (21%) and 52.5% of patients (n=105) were using at least one psychotropic medication. Patients with CA had higher rates of psychotropic medication use (p=0.010) and the most frequently used medication group was antipsychotic drugs (92.4%).


Conclusion: Treatment approaches utilized in rural hospitals are in line with the universal trends. However, considerably higher MDA compared to previous studies show that; to provide early diagnosis and better prognosis for ASD patients who live in rural areas, new interventions should be promoted by the local and/or general authorities.

Downloads

Download data is not yet available.

Article Details

How to Cite
Besenek, M. (2021). Autism Spectrum Disorder Referrals to a Rural Hospital in the Past Two Years – A Retrospective Evaluation. Medical Science and Discovery, 8(1), 14-18. https://doi.org/10.36472/msd.v8i1.449
Section
Research Article

References

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5). Diagnostic Stat Man Ment Disord 4th Ed TR. 2013;280.



2. Baio J, Wiggins L, Christensen DL, Maenner MJ, Daniels J, Warren Z, et al. Prevalence of autism spectrum disorder among children aged 8 Years - Autism and developmental disabilities monitoring network, 11 Sites, United States, 2014. MMWR Surveill Summ. 2018;67(6):1-23. DOI: 10.15585/mmwr.ss6706a1

3. Mandell DS, Novak M. The role of culture in families’ treatment decisions for children with autism spectrum disorders. Mental Retardation and Developmental Disabilities Research Reviews. 2005;11:110–5.

4. Committee to Evaluate the Supplemental Security Income Disability Program for Children with Mental Disorders; Board on the Health of Select Populations; Board on Children, Youth, and Families; Institute of Medicine; Division of Behavioral and Social Scien and M. Clinical Characteristics of Autism Spectrum Disorder. In: Boat T, Wu J, editors. Mental Disorders and Disabilities Among Low-Income Children. Washington DC: National Academies Press; 2015.

5. Fombonne E. Epidemiology of autistic disorder and other pervasive developmental disorders. J Clin Psychiatry. 2005;66(10):3–8.

6. Young N, Findling RL. An update on pharmacotherapy for autism spectrum disorder in children and adolescents. Current Opinion in Psychiatry. 2015;28(2):91–101. DOI: 10.1097/YCO.0000000000000132

7. Coury DL, Anagnostou E, Manning-Courtney P, Reynolds A, Cole L, McCoy R, et al. Use of psychotropic medication in children and adolescents with autism spectrum disorders. Pediatrics. 2012;130(SUPPL. 2):69-76. DOI: 10.1542/peds.2012-0900D

8. World Health Organization. International Statistical Classification of Diseases and Related Health Problems. 10th Revis. 2004.

9. IBM SPSS statistics for Windows. IBM Corporation; 2018.

10. Uğur Ç, Göker Z. Autism Spectrum Disorders in Cases Presenting to a Child Psychiatry Department: Demographics and Clinical Features. Turkish J Pediatr Dis. 2019;3:177–83.

11. Helt M, Kelley E, Kinsbourne M, Pandey J, Boorstein H, Herbert M, et al. Can children with autism recover? If so, how? Neuropsychol Rev. 2008;18(4):339–66. DOI: 10.1007/s11065-008-9075-9

12. Posar A, Visconti P. Long-term outcome of autism spectrum disorder. Turkish Achives Pediatr. 2019;54(4):207–12.

13. Arnold LE, Vitiello B, McDougle C, Scahill L, Shah B, Gonzalez NM, et al. Parent-defined target symptoms respond to risperidone in RUPP Autism study: Customer approach to clinical trials. J Am Acad Child Adolesc Psychiatry. 2003;42(12):1443–50. DOI: 10.1097/00004583-200312000-00011

14. Kanne SM, Mazurek MO. Aggression in children and adolescents with ASD: Prevalence and risk factors. J Autism Dev Disord. 2011;41(7):926–37. DOI: 10.1007/s10803-010-1118-4

15. Ibrahim K, Eilbott JA, Ventola P, He G, Pelphrey KA, McCarthy G, et al. Reduced Amygdala–Prefrontal Functional Connectivity in Children With Autism Spectrum Disorder and Co-occurring Disruptive Behavior. Biol Psychiatry Cogn Neurosci Neuroimaging. 2019;4(12):1031–41. DOI: 10.1016/j.bpsc.2019.01.009

16. Mazurek MO, Kanne SM, Wodka EL. Physical aggression in children and adolescents with autism spectrum disorders. Res Autism Spectr Disord. 2013;7(3):455–65.

17. Taurines R, Schwenck C, Westerwald E, Sachse M, Siniatchkin M, Freitag C. ADHD and autism: Differential diagnosis or overlapping traits? A selective review. Atten Defic Hyperact Disord. 2012;4(3):115–39. DOI: 10.1007/s12402-012-0086-2





18. Kent JM, Kushner S, Ning X, Karcher K, Ness S, Aman M, et al. Risperidone dosing in children and adolescents with autistic disorder: A double-blind, placebo-controlled study. J Autism Dev Disord. 2013;43(8):1773–83. DOI: 10.1007/s10803-012-1723-5

19. Marcus RN, Owen R, Kamen L, Manos G, McQuade RD, Carson WH, et al. A Placebo-Controlled, Fixed-Dose Study of Aripiprazole in Children and Adolescents With Irritability Associated With Autistic Disorder. J Am Acad Child Adolesc Psychiatry. 2009;48(11):1110–9. DOI: 10.1097/CHI.0b013e3181b76658

20. Owen R, Sikich L, Marcus RN, Corey-Lisle P, Manos G, McQuade RD, et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics. 2009;124(6):1533–40. DOI: 10.1542/peds.2008-3782

21. Hollander E, Wasserman S, Swanson EN, Chaplin W, Schapiro ML, Zagursky K, et al. A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. J Child Adolesc Psychopharmacol. 2006;16(5):541–8. DOI: 10.1089/cap.2006.16.541

22. Anderson LT, Campbell M, Adams P, Small AM, Perry R, Shell J. The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children. J Autism Dev Disord. 1989;19(2):227–39. DOI: 10.1007/BF02211843

23. Posey DJ, Aman MG, Arnold LE, Ramadan Y, Witwer A, Lindsay R, et al. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiatry. 2005;62(11):1266–74. DOI: 10.1001/archpsyc.62.11.1266

24. Jahromi LB, Kasari CL, McCracken JT, Lee LSY, Aman MG, McDougle CJ, et al. Positive effects of methylphenidate on social communication and self-regulation in children with pervasive developmental disorders and hyperactivity. J Autism Dev Disord. 2009;39(3):395–404. DOI: 10.1007/s10803-008-0636-9

25. Handen BL, Aman MG, Arnold LE, Hyman SL, Tumuluru R V., Lecavalier L, et al. Atomoxetine, Parent Training, and Their Combination in Children With Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder. J Am Acad Child Adolesc Psychiatry. 2015;54(11):905–15. DOI: 10.1016/j.jaac.2015.08.013

26. Harfterkamp M, Van De Loo-Neus G, Minderaa RB, Van Der Gaag RJ, Escobar R, Schacht A, et al. A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder. J Am Acad Child Adolesc Psychiatry. 2012;51(7):733–41. DOI: 10.1016/j.jaac.2012.04.011



























27. Neyzi O, Günöz H, Furman A, Bundak R, Gökçay G, Darendeliler F, et al. Türk çocuklarında vücut ağırlığı, boy uzunluğu, baş çevresi ve vücut kitle indeksi referans değerleri. Çocuk Sağlığı ve Hast Derg. 2008;51:1–14.

28. King BH, Hollander E, Sikich L, McCracken JT, Scahill L, Bregman JD, et al. Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: Citalopram ineffective in children with autism. Arch Gen Psychiatry. 2009;66(6):583–90. DOI: 10.1001/archgenpsychiatry.2009.30

29. Autism Speaks. Autism Speaks Announces Results Reported for the Study of Fluoxetine in Autism (SOFIA) [Internet]. 2009. Available from: http://www.autism-speaks.org/about-us/press-release/autism-speaks-announces-results-reported-study-fluoxetine-austism-sofia

30. Williams K, Brignell A, Randall M, Silove N, Hazell P. Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). Cochrane Database of Systematic Reviews. 2013;20(8):CD004677. DOI: 10.1002/14651858.CD004677.pub3

31. Hollander E, Soorya L, Wasserman S, Esposito K, Chaplin W, Anagnostou E. Divalproex sodium vs. placebo in the treatment of repetitive behaviours in autism spectrum disorder. Int J Neuropsychopharmacol. 2006;9(2):209–13. DOI: 10.1017/S1461145705005791

32. Hollander E, Chaplin W, Soorya L, Wasserman S, Novotny S, Rusoff J, et al. Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders. Neuropsychopharmacology. 2010;35(4):990–8.

33. Hellings JA, Weckbaugh M, Nickel EJ, Cain SE, Zarcone JR, Reese RM, et al. A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2005;15(4):682–92. DOI: 10.1089/cap.2005.15.682

34. Cortesi F, Giannotti F, Sebastiani T, Panunzi S, Valente D. Controlled-release melatonin, singly and combined with cognitive behavioural therapy, for persistent insomnia in children with autism spectrum disorders: A randomized placebo-controlled trial. J Sleep Res. 2012;21(6):700–9. DOI: 10.1111/j.1365-2869.2012.01021.x